Publications by authors named "John F Neylan"

Claim this Profile
P
Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function.
Flavio Vincenti, Jim Kim, Deborah Gouveia, Gabrielle Pelle, Tracy J Mayne, John F Neylan

Kidney Int Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury.
Sabry Ayad, John F Neylan, Tracy J Mayne, Deborah Gouveia, Madhav Swaminathan

Kidney Int Rep· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Geoffrey A Block, Pablo E Pergola, Steven Fishbane, Julian G Martins, Robin D LeWinter, John F Neylan

Nephrol Dial Transplant· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
Peter A McCullough, Katrin Uhlig, John F Neylan, Pablo E Pergola, Steven Fishbane

Am J Cardiol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia.
Pablo E Pergola, Steven Fishbane, Robin D LeWinter, John F Neylan, Katrin Uhlig

Am J Hematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.
Glenn M Chertow, Geoffrey A Block, John F Neylan, Pablo E Pergola, Katrin Uhlig

PLoS One· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
Josefina Alberú, Michael D Pascoe, Josep M Campistol, Francesco P Schena, Maria Del Carmen Rial, John F Neylan

Transplantation· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Francesco P Schena, Michael D Pascoe, Josefina Alberu, Maria del Carmen Rial, Rainer Oberbauer, John F Neylan

Transplantation· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
A Osama Gaber, Barry D Kahan, Charles Van Buren, Seth L Schulman, Joseph Scarola, John F Neylan

Transplantation· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression.
James T Burke, Yves Brault, Barry D Kahan, Donald E Hricik, Josep M Grinyó, John F Neylan

Transpl Int· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
Christophe Legendre, Yves Brault, José M Morales, Rainer Oberbauer, Paolo Altieri, John F Neylan

Clin Transplant· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
Josep M Campistol, Josette Eris, Rainer Oberbauer, Peter Friend, Brian Hutchison, John F Neylan

J Am Soc Nephrol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Graeme Russ, Giuseppe Segoloni, Rainer Oberbauer, Christophe Legendre, Alfredo Mota, John F Neylan

Transplantation· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
Rainer Oberbauer, Giuseppe Segoloni, Josep M Campistol, Henri Kreis, Alfredo Mota, John F Neylan

Transpl Int· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years.
Alfredo Mota, Manuel Arias, Eero I Taskinen, Timo Paavonen, Yves Brault, John F Neylan

Am J Transplant· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.
Henri Kreis, Rainer Oberbauer, Josep M Campistol, Timothy Mathew, Pierre Daloze, John F Neylan

J Am Soc Nephrol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of Duffy blood group on renal allograft outcome in African Americans.
Enver Akalin, John F Neylan

Transplantation· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis